Haoyuan's FDA clearance, profit growth and China drug policy lift shares
FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.
A concrete regulatory milestone that expands the addressable market and supports future earnings.
First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.
The half-year results are the clearest evidence of the company's underlying earnings trend.
Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.
Dividend policy is a direct signal of financial health and shareholder returns.
15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.
Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.